MicroVision, Inc.
9.5.2023 23:02:10 CEST | ACCESS Newswire | Press release
REDMOND, WA / ACCESSWIRE / May 9, 2023 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its first quarter 2023 results.
"Following the closing in January of our acquisition of assets from Ibeo Automotive Systems GmbH, we are energized by the strength of our combined team, accelerated engagement with multiple OEMs, and positive financial performance in Q1 2023. Revenue of $0.8 million was ahead of our expectations, primarily driven by the acquisition." said Sumit Sharma, MicroVision's Chief Executive Officer. "I am pleased with our significant achievements in the first quarter, with the momentum in our top line driven by our expanded product offerings and the efficient integration of our U.S. and Germany teams.
"With the dynamic-view MAVIN™, our MEMS-based scanning lidar for long-range highway pilot; MOVIA™, our flash-based short-range lidar for automotive and non-automotive applications; and MOSAIK™, our validation software suite for OEMs and Tier 1s, MicroVision is uniquely positioned to capture meaningful market share in both automotive and non-automotive verticals," continued Sharma. "Our product offerings and unmatched technical capabilities are proving to be compelling in key RFIs and RFQs from several OEMs around the globe. We maintain our 2023 revenue guidance of $10-15 million from our expanded product suite."
Key Financial Highlights for Q1 2023
- Revenue for the first quarter of 2023 was $0.8 million, compared to $0.4 million for the first quarter of 2022. The revenue growth in the first quarter was primarily due to the IBEO acquisition and includes the sale of lidar hardware and related software to various customers.
- Net loss for the first quarter of 2023 was $19.0 million, or $0.11 per share, which includes $2.9 million of non-cash, share-based compensation expense, $1.7 million bargain purchase price gain, compared to a net loss for the first quarter of 2022 of $13.2 million, or $0.08 per share, which includes $3.7 million of non-cash, share-based compensation expense.
- Adjusted Gross Profit for the first quarter of 2023 was a $0.5 million, compared to a $0.3 million for the first quarter of 2022.
- Adjusted EBITDA for the first quarter of 2023 was a $15.8 million loss, compared to a $9.0 million loss for the first quarter of 2022.
- Cash used in operations in the first quarter of 2023 was $13.8 million, compared to cash used in operations in the first quarter of 2022 of $10.9 million.
- The Company ended the first quarter of 2023 with $67.7 million in cash and cash equivalents including investment securities, compared to $82.7 million at December 31, 2022.
Conference Call and Webcast: Q1 2023 Results
MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 2:00 PM PT/5:00 PM ET on Tuesday, May 9, 2023 to discuss the financial results and provide a business update. Analysts and investors may pose questions to management during the live webcast on May 9, 2023.
The live webcast and slide presentation can be accessed on the Company's Investor Relations website under the Events tab at https://ir.microvision.com/events. The webcast will be archived on the website for future viewing.
About MicroVision
With over 350 employees and global presence in Redmond, Detroit, Hamburg, and Nuremberg, MicroVision is a pioneering company in MEMS-based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company's integrated approach uses its proprietary technology to provide automotive lidar sensors and solutions for advanced driver-assistance systems (ADAS) and for non-automotive applications including industrial, smart infrastructure and robotics. The Company has been leveraging its experience building augmented reality micro-display engines, interactive display modules, and consumer lidar modules.
For more information, visit the Company's website at www.microvision.com, on Facebook at www.facebook.com/microvisioninc, and LinkedIn at https://www.linkedin.com/company/microvision/.
MicroVision, MAVIN, MOSAIK, and MOVIA are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.
Non-GAAP information
To supplement MicroVision's condensed financial statements presented in accordance with GAAP, the Company presents investors with the non-GAAP financial measure "adjusted EBITDA" and "adjusted Gross Profit." Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; and share-based compensation. Adjusted Gross Profit is calculated as GAAP gross profit before stock-based compensation expense and the amortization of acquired intangibles included in cost of revenue.
MicroVision believes that the presentation of adjusted EBITDA and adjusted Gross Profit provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision's past financial reports, and facilitates comparisons with other companies in the Company's industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses this non-GAAP measure when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company's operating results and facilitates comparisons of the Company's core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA and adjusted Gross Profit is useful to investors in their assessment of MicroVision's operating performance and the valuation of the Company.
Adjusted EBITDA and adjusted Gross Profit is not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision's business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from its non-GAAP financial measure should not be construed as an inference that these costs are unusual or infrequent. The Company compensates for limitations of the measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.
Similarly for Adjusted Gross Profit, the Company compensates for limitations of the measure by prominently disclosing GAAP gross profits which is the difference between Revenue and Cost of revenue, which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation by backing out stock-based compensation expense and the amortization of acquired intangibles included in cost of revenue.
Forward-Looking Statements
Certain statements contained in this release, including the Company's plans regarding benefits of the acquisition, market position, product portfolio, product capabilities, and expected revenue, expenses and cash usage are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements, including from the impact of COVID-19 (coronavirus); its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.
Investor Relations Contact
Jeff Christensen
Darrow Associates Investor Relations
MVIS@darrowir.com
Media Contact
Robyn Komachi
Marketing@MicroVision.com
MicroVision, Inc.
Consolidated Balance Sheet
(In thousands)
(Unaudited)
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
Assets | ||||||||
Current Assets | ||||||||
Cash and cash equivalents | $ | 23,187 | $ | 20,536 | ||||
Investment securities, available-for-sale | 44,544 | 62,173 | ||||||
Restricted cash, current | 3,263 | - | ||||||
Accounts receivable, net | 506 | - | ||||||
Contract assets | 192 | - | ||||||
Inventory | 3,116 | 1,861 | ||||||
Advance to IBEO | - | 4,132 | ||||||
Other current assets | 2,182 | 2,306 | ||||||
Total current assets | 76,990 | 91,008 | ||||||
Property and equipment, net | 10,284 | 6,830 | ||||||
Operating lease right-of-use asset | 14,746 | 14,579 | ||||||
Restricted cash | 961 | 1,418 | ||||||
Intangible assets, net | 19,000 | 75 | ||||||
Other assets | 1,281 | 1,086 | ||||||
Total assets | $ | 123,262 | $ | 114,996 | ||||
Liabilities and Shareholders' Equity | ||||||||
Current Liabilities | ||||||||
Accounts payable | $ | 3,629 | $ | 2,061 | ||||
Accrued liabilities | 10,414 | 2,058 | ||||||
Contract liabilities | 5,676 | 4,601 | ||||||
Other current liabilities | 211 | 839 | ||||||
Current portion of operating lease liability | 2,210 | 1,846 | ||||||
Current portion of finance lease obligations | 15 | 21 | ||||||
Total current liabilities | 22,155 | 11,426 | ||||||
Operating lease liability, net of current portion | 13,729 | 13,829 | ||||||
Deferred tax liabilities | 823 | - | ||||||
Total liabilities | 36,724 | 25,255 | ||||||
Commitments and contingencies | ||||||||
Shareholders' Equity | ||||||||
Common stock at par value | 176 | 171 | ||||||
Additional paid-in capital | 787,856 | 772,221 | ||||||
Accumulated other comprehensive loss | 57 | (127 | ) | |||||
Accumulated deficit | (701,551 | ) | (682,524 | ) | ||||
Total shareholders' equity | 86,538 | 89,741 | ||||||
Total liabilities and shareholders' equity | $ | 123,262 | $ | 114,996 | ||||
MicroVision, Inc.
Consolidated Statement of Operations
(In thousands, except earnings per share data)
(Unaudited)
| Three months ended March 31, | ||||||||
| 2023 | 2022 | |||||||
Revenue | $ | 782 | $ | 350 | ||||
Cost of revenue | 544 | 4 | ||||||
Gross profit | 238 | 346 | ||||||
Research and development expense | 12,692 | 7,593 | ||||||
Sales, marketing, general and administrative expense | 8,737 | 5,877 | ||||||
Total operating expenses | 21,429 | 13,470 | ||||||
Loss from operations | (21,191 | ) | (13,124 | ) | ||||
Bargain purchase gain, net of tax | 1,706 | - | ||||||
Other income (expense), net | 639 | (44 | ) | |||||
Net loss before taxes | $ | (18,846 | ) | $ | (13,168 | ) | ||
Income tax expense | (181 | ) | - | |||||
Net income (loss) | $ | (19,027 | ) | $ | (13,168 | ) | ||
Net income (loss) per share - basic and diluted | $ | (0.11 | ) | $ | (0.08 | ) | ||
Weighted-average shares outstanding - basic and diluted | 174,703 | 164,563 | ||||||
MicroVision, Inc.
Consolidated Statement of Cash Flows
(In thousands)
(Unaudited)
Three months ended March 31, | ||||||||
| 2023 | 2022 | |||||||
Cash flows from operating activities | ||||||||
Net loss | $ | (19,027 | ) | $ | (13,168 | ) | ||
Adjustments to reconcile net loss to net cash used in operations: | ||||||||
Depreciation and amortization | 2,271 | 483 | ||||||
Bargain purchase gain, net of tax | 1,706 | - | ||||||
Impairment of property and equipment | - | 60 | ||||||
Share-based compensation expense | 2,949 | 3,734 | ||||||
Inventory write-downs | 29 | - | ||||||
Net accretion of premium on short-term investments | (396 | ) | 160 | |||||
Change in | ||||||||
Accounts receivable | (506 | ) | - | |||||
Contract assets | (192 | ) | - | |||||
Inventory | (87 | ) | (35 | ) | ||||
Other current and non-current assets | 647 | 389 | ||||||
Accounts payable | 1,629 | (1,292 | ) | |||||
Accrued liabilities | (2,367 | ) | 118 | |||||
Contract liabilities and other current liabilities | 195 | (1,057 | ) | |||||
Operating lease liabilities | (669 | ) | (299 | ) | ||||
Other clong-term liabilities | 17 | - | ||||||
Net cash used in operating activities | (13,801 | ) | (10,907 | ) | ||||
Cash flows from investing activities | ||||||||
Sales of investment securities | 22,000 | 1,500 | ||||||
Purchases of investment securities | (3,898 | ) | (16,696 | ) | ||||
Acquisition of Ibeo assets | (10,914 | ) | - | |||||
Purchases of property and equipment | (615 | ) | (884 | ) | ||||
Net cash provided by (used in) investing activities | 6,573 | (16,080 | ) | |||||
Cash flows from financing activities | ||||||||
Principal payments under finance leases | (6 | ) | (8 | ) | ||||
Principal payments under long-term debt | - | (294 | ) | |||||
Proceeds from stock option exercises | - | 253 | ||||||
Net proceeds from issuance of common stock | 12,691 | - | ||||||
Net cash provided by financing activities | 12,685 | (49 | ) | |||||
Change in cash, cash equivalents, and restricted cash | 5,457 | (27,036 | ) | |||||
Cash, cash equivalents and restricted cash at beginning of period | 21,954 | 83,739 | ||||||
Cash, cash equivalents and restricted cash at end of period | $ | 27,411 | $ | 56,703 | ||||
| The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of | ||||||||
March 31, 2023 and December 31, 2022: | ||||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
Cash and cash equivalents | $ | 23,187 | $ | 20,536 | ||||
Restricted cash | 4,224 | 1,418 | ||||||
Cash, cash equivalents and restricted cash | 27,411 | 21,954 | ||||||
MicroVision, Inc.
Reconciliation of GAAP to Non-GAAP Measures
(In thousands, except earnings per share data)
(Unaudited)
Three months ended March 31, | ||||||||
| 2023 | 2022 | |||||||
Reconciliation of Non-GAAP Gross Profit: | ||||||||
Gross Profit | $ | 238 | $ | 346 | ||||
Share-based compensation expense | - | - | ||||||
Amortization of acquired intangibles | 255 | - | ||||||
Non-GAAP Gross Profit | $ | 493 | $ | 346 | ||||
Reconciliation of GAAP Net Loss to Non-GAAP Measure: | ||||||||
GAAP net loss | $ | (19,027 | ) | $ | (13,168 | ) | ||
Add Interest (net) | (499 | ) | (31 | ) | ||||
Add Income taxes | 181 | - | ||||||
Add Depreciation & amorization | 2,271 | 483 | ||||||
Add Bargain purchase gain | (1,706 | ) | - | |||||
Add Share-based compensation expense | 2,949 | 3,734 | ||||||
Adjusted EBITDA | $ | (15,831 | ) | $ | (8,982 | ) | ||
SOURCE: MicroVision, Inc.
View source version on accesswire.com:
https://www.accesswire.com/753823/MicroVision-Announces-First-Quarter-2023-Results
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Partnering With Spirit Defense For FQ-42 CCA Production23.10.2026 18:00:00 CEST | Press release
SAN DIEGO, CA / ACCESS Newswire / October 23, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI), the world leader in Uncrewed Aircraft Systems (UAS), today is announcing our partnership with Spirit Defense, a Boeing Company, to support airframe production of the new FQ-42 Vengeance Collaborative Combat Aircraft (CCA). In June, GA-ASI won a contract from the U.S. Air Force (USAF) to produce FQ-42. Spirit Defense's role as a fuselage design-build partner brings together the company's engineering and advanced manufacturing capabilities to support the program from design through production. GA-ASI has been the sole manufacturer of its line of UAS - which includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian - since the company's inception in 1992. For the FQ-42 program, partnering with Spirit Defense is a strength multiplier for the company and the nation, offering manufacturing capacity and industrial depth to scale CCA production faster, w
Study Finds Lower Rates of Overweight Among Vegan-Fed Cats23.10.2026 16:45:00 CEST | Press release
LONDON, UK / ACCESS Newswire / October 23, 2026 / A large-scale survey published in Frontiers in Animal Science has found cats fed vegan diets had lower rates of obesity and related health problems, than those fed conventional meat-based diets. An online survey analysed carer-reported veterinary assessments of 1,305 cats fed either conventional meat-based (90%) or vegan (10%) diets for at least one year. After accounting for factors including age, sex, neuter status, activity and feeding practices, vegan-fed cats had 34% lower odds of being assessed as overweight. However, the difference was not statistically significant, in part reflecting the relatively small number of vegan-fed cats. For several body weight-related problems, no vegan-fed cats were affected. Nevertheless, researchers say the findings show an interesting trend that warrants further investigation. Overweight and obesity are common in domestic cats, with veterinary studies estimating that around 30-60% of cats are overw
Leggett Dynamics's Mid-Class Massage System Wins Gasgoo's Best Technical Practice Award23.10.2026 16:00:00 CEST | Press release
SHANGHAI, CHINA / ACCESS Newswire / October 23, 2026 / Leggett Dynamics today announced that its Mid-Class Massage System (MCM) received Gasgoo's Best Technical Practice Award during a ceremony held at the 14th annual Automotive & Environment Innovation Forum in Shanghai. The Gasgoo Best Technical Practice Award honors automotive technologies that have proven innovation, production readiness and measurable customer value in real-world vehicle applications. The judging panel cited MCM's innovation that achieves affordable, premium-level comfort for mid-class vehicle programs. About Leggett Dynamics' Mid-Class Massage System Leggett Dynamics' MCM is a comfort innovation that expands premium massage technology beyond the luxury vehicle segment. Already in serial production with a leading global OEM and generating strong interest from multiple global automakers, the innovation delivers a premium massage experience while reducing system cost and complexity through the intelligent use of pre
New Global Initiative Seeks to Modernize Health Workforce Mobility22.10.2026 17:00:00 CEST | Press release
PHILADELPHIA, PA, TORONTO, ON AND GRONINGEN, NETHERLANDS / ACCESS Newswire / October 22, 2026 / TruMerit® and Centennial College, with support of the Groningen Declaration Network (GDN Network), have unveiled a new vision for the future of global health workforce mobility, introducing a framework designed to help health professionals carry trusted, verifiable records of their qualifications and competencies across borders. The initiative is detailed in a newly published paper titled "Toward a Global Digital Credential Mobility Ecosystem for Migrating Health Professionals." As healthcare systems worldwide face persistent workforce shortages, internationally educated health professionals often encounter lengthy, duplicative, and inconsistent credential recognition processes that can delay entry into practice. The paper proposes a new approach centered on a Global Competency Record (GCR). This portable digital record could securely bring together verified evidence of a professional's educ
P&G, Nestlé, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards22.10.2026 15:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / October 22, 2026 / OMP, a leader in AI-powered supply chain solutions, recently honored six global brands at its conferences held earlier this month in Singapore and Shanghai. The recognized companies - Procter & Gamble (P&G), Nestlé, Mars, AstraZeneca, ITC, and Bekaert - were celebrated for driving decision velocity, co-innovation, and impactful business results. Supply Chain Innovation & Excellence Award: Nestlé and Bekaert Nestlé, one of the world's largest food and beverage companies, and Bekaert, a global market and technology leader in material science of steel wire transformation and coating technologies, received OMP's Supply Chain Innovation & Excellence award for their breadth of deployment and depth of co-innovation.Nestlé aligns its supply network at the strategic, tactical, and operational levels on OMP's Unison Planning™ platform, connecting forecasting, planning, and replenishment end-to-end. As more routine work becomes touchless, plann
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
